New drug delivers breakthrough results in narcolepsy treatment
Orexoborikston, a new medication, has shown remarkable results in clinical trials for narcolepsy, offering hope for improved management of the disorder.
Key Takeaways
AIA new drug is poised to transform the treatment of narcolepsy, after clinical trials revealed promising results for 'Orexoborikston', which targets a key brain chemical essential for regulating sleep and wakefulness.
Orexoborikston works by activating orexin-2 receptors in the brain, stimulating the production of orexin—a substance produced by cells in the hypothalamus. Orexin not only regulates sleep and wakefulness, but is also linked to attention, motivation, and the brain’s reward system, according to Russia Today.
In clinical trials involving more than 270 narcolepsy patients, participants took Orexoborikston twice daily for three months. Results published by the drug’s manufacturer, Takeda, showed a significant improvement in daytime alertness, along with an average 80% reduction in cataplexy episodes.
Type 1 narcolepsy, the most common form accounting for about 75% of cases, is associated with the loss of cells responsible for producing orexin. This is believed to result from an immune system malfunction that mistakenly attacks these cells, leading to lower orexin levels and disrupted sleep-wake regulation in the brain.
Last month, the US Food and Drug Administration approved Orexoborikston for the treatment of narcolepsy. In the United Kingdom, the National Institute for Health and Care Excellence (NICE) is currently assessing whether to provide the drug through the National Health Service.